USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
04 Aug 2022 | 02:45 PM GMT

Sprint: How to Overcome the Blockers to DTx Adoption and Measure Success? (Part 1)

Anchored by:

Mette Dyhrberg
Founder & CEO
MYMEE

Participants:

Mette Dyhrberg Founder & CEOMymee
Mette Dyhrberg
Founder & CEOMymee
Jo Peddhinti AdvisoryHLTH Community
Jo Peddhinti
AdvisoryHLTH Community
Adriano Garcez Director, DTx/SaMD Evidence GenerationZS Associates
Adriano Garcez
Director, DTx/SaMD Evidence GenerationZS Associates
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Hannes Klöpper FounderHelloBetter
Hannes Klöpper
FounderHelloBetter
Ricardo C. Berrios Co-Founder & CEOAdhera Health, Inc.
Ricardo C. Berrios
Co-Founder & CEOAdhera Health, Inc.
Rich DeNunzio Chief Commercial OfficerClick Therapeutics
Rich DeNunzio
Chief Commercial OfficerClick Therapeutics
Richie Bavasso PresidentPneumoWave
Richie Bavasso
PresidentPneumoWave

About this Meeting

While new legislations and rules (such as DiGA in Germany) have opened new options for reimbursement, adoption of digital therapeutics (DTx) remains insufficient to achieve the revenue expected from these solutions. Significant investments in marketing and sales are needed to engage patients, but on top of that, there is a major big challenge in educating and convincing doctors.  

No one has found the silver bullet yet, but a mix of the traditional and innovative strategies could prove successful. At this series of two meetings we will break down the blockers to adoption, examples to overcome these and what success looks like for a DTx: 

  • SESSION 1 (August 4th): blockers to DTx adoption and how to overcome these
    - One of the main blockers to DTx adoption is physicians awareness and education. When talking with physicians, how can companies demonstrate a DTx can be seamlessly implemented in their daily routine and provide value?
    - Activating and engaging patients is a huge challenge too and identifying the early adopters have proven successful. How can companies find the early adopters that can produce real-world evidence and patient testimonies? How can companies balance the potential cost of a Randomized Control Trial (RCT) against the cost of focusing on building a user base for a B2C product, taking into account user acquisition costs?  
  • SESSION 2 (25th August): how do we measure the adoption success for DTx?
    - What does successful adoption look like? Are there clear examples in the market that are the role model for other DTx companies?
    - Do we have transparency on the nuances across the different types of DTx, geographies and therapeutic areas?
    - How can companies use data analytics to define and measure adoption success?